Pyrotinib alone or in combination with docetaxel in refractory HER2 ‐positive gastric cancer: A dose‐escalation phase I study
Cancer Medicine · 2023
DOI: 10.1002/cam4.5830 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Dan Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Early Drug Development Center, Peking University Cancer Hospital…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Breast Neoplasms, Neutropenia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Aim
Pyrotinib (an irreversible pan‐ErbB small‐molecular tyrosine kinase inhibitor) was approved in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and showed great antitumor activity in preclinical studies of gastric cancer (GC). This study was first designed to prospectively assess pyrotinib in pretreated HER2‐positive GC.
Methods
This multicenter, phase I study followed a standard “3 + 3” design and included two parts. In the pyrotinib part, pyrotinib was administered orally, once per day at dose levels of 240, 320, 400, and 480 mg. In the pyrotinib plus docetaxel part, patients received pyrotinib (qd, d1‐21, q3W) combined with docetaxel (60 mg/m 2 , d1, q3W) at dose levels of 240, 320, and 400 mg. Primary endpoints were to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of pyrotinib as monotherapy or coadministered with docetaxel.
Results
A total of 25 patients were enrolled and received pyrotinib ( n = 15) or pyrotinib plus docetaxel ( n = 10). One DLT was observed in pyrotinib monotherapy part (Grade 3 uncontrolled diarrhea after supportive care) and pyrotinib plus docetaxel part (Grade 4 neutropenia and leukopenia). In the pyrotinib monotherapy part, MTD was not reached. Diarrhea, anemia, neutropenia, and leukopenia were the most common treatment‐related adverse events (TRAEs). The RP2D for pyrotinib monotherapy was recommended as 400 mg. After combining with docetaxel, the risk of leukopenia and neutropenia was increased. Grade ≥3 TRAEs were reported for four patients in the monotherapy part and for eight patients in the combination part. Mean t 1/2 was approximately 20 h. Pyrotinib exposure was dose‐dependent with a nonlinear relationship versus dose. There were five patients who had confirmed partial response (monotherapy: one each at 240, 400, and 480 mg dose cohort; combination therapy: two at 240 mg dose cohort), resulting in an objective response rate of 21% and 20%, respectively.
Conclusions
Pyrotinib alone and combined with docetaxel showed acceptable toxicities in patients with pretreated HER2‐positive GC. Trial Registration This study was registered with ClinicalTrials.gov , NCT02378389.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Day Oncology Unit, Peking University Cancer Hospital & Institute, Beijing, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology/Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Jiangsu Hengrui Medicine Co., Ltd, Lianyungang, China.
ORCID-Profile: Furong Kou, Jian Li, Jun Zhou, Zhihao Lu, Lin Shen
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, D., Kou, F., Gong, J., Wang, Z., Zhang, X., Li, J., Li, Y., Li, J., Zhou, J., Lu, M., Wang, X., Lu, Z., Cao, Y., Zou, J., Zhu, X., Xu, R., & Shen, L. (2023). Pyrotinib alone or in combination with docetaxel in refractory HER2 ‐positive gastric cancer: A dose‐escalation phase I study. Cancer Medicine. https://doi.org/10.1002/cam4.5830
Vancouver
Liu D, Kou F, Gong J, Wang Z, Zhang X, Li J, et al. Pyrotinib alone or in combination with docetaxel in refractory HER2 ‐positive gastric cancer: A dose‐escalation phase I study. Cancer Medicine. 2023. doi:10.1002/cam4.5830
BibTeX
@article{Liu2023,
author = {Liu, Dan and Kou, Furong and Gong, Jifang and Wang, Zhiqiang and Zhang, Xiaotian and Li, Jian and Li, Yan and Li, Jie and Zhou, Jun and Lu, Ming and Wang, Xicheng and Lu, Zhihao and Cao, Yanshuo and Zou, Jianjun and Zhu, Xiaoyu and Xu, Ruihua and Shen, Lin},
title = {Pyrotinib alone or in combination with docetaxel in refractory HER2 ‐positive gastric cancer: A dose‐escalation phase I study},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.5830}
}
EUVIMED